Related Experiment Video
Updated: Jun 10, 2026
08:34
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
[Probiotic therapy using live combined bifidobacterium, lactobacillus and enterococcus for experimental colitis in
Yue-meng Wan1, You-qing Zhu, Bing Xia
1Department of Gastroenterology, Zhongnan Hospital, Medical School of Wuhan University, Wuhan 430071, China.
Zhonghua Nei Ke Za Zhi
|July 22, 2010
Summary
Live combined probiotics effectively reduced colitis in TNBS-induced rats. This probiotic therapy may offer a novel treatment for inflammatory bowel diseases by modulating cytokine levels.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Context:
- Inflammatory bowel diseases (IBD) represent a significant health challenge.
- Current therapies for IBD have limitations, necessitating novel treatment strategies.
- Animal models, such as TNBS-induced colitis in rats, are crucial for evaluating potential IBD therapies.
Purpose:
- To investigate the therapeutic efficacy of live combined Bifidobacterium, Lactobacillus, and Enterococcus capsules in a rat model of colitis.
- To explore the potential mechanisms underlying the observed therapeutic effects, focusing on inflammatory markers and cytokines.
Summary:
- This study evaluated the effects of live combined probiotics in TNBS-induced colitis in rats.
- Probiotic treatment, alone or in combination with olsalazine, significantly reduced colonic inflammation, myeloperoxidase activity, and C-reactive protein levels.
- Key inflammatory cytokines, TNFα and IL-10, were modulated by the probiotic intervention, correlating with reduced colonic damage.
Impact:
- Live combined probiotics demonstrate significant potential as an effective therapeutic agent for colitis.
- The findings suggest a novel therapeutic avenue for inflammatory bowel diseases, potentially through the modulation of cytokine profiles.
- This research provides a foundation for further clinical investigations into probiotic-based treatments for IBD.
